Відмінності між версіями «Le disease in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | + | These sufferers are viewed as to have achieved a minimal residual illness (MRD) negative status.17-20 Various phase II trials have demonstrated that sufferers reaching MRD negativity have a signif-icantly longer survival than people that stay MRD optimistic, and that is true for patients treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 In addition, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers getting MRD negativity had drastically longer progression-free and overall survivals, irrespectively in the therapy received.18 Unfortunately, nonetheless, some of these research have been flawed by inappropriate statistical evaluation, specifically the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are many caveats to the use of MRD evaluation in sufferers with CLL.28 First, CLL remains incurable and at the least 30 of sufferers who achieve MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point practical experience a disease relapse within five years.18 Secondly, unlike the scenario in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic benefit of re-treatment upon [http://www.medchemexpress.com/STF-62247.html STF 62247 site] documentation of MRD positivity immediately after an initial MRD-negative response in comparison to therapy at the time of clinical relapse. These sufferers are viewed as to have achieved a minimal residual disease (MRD) damaging status.17-20 Quite a few phase II trials have demonstrated that individuals attaining MRD negativity possess a signif-icantly longer survival than individuals who remain MRD positive, and that is correct for patients treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 In addition, a phase III trial performed by the German CLL Study Group (GCLLSG) recently revealed that individuals acquiring MRD negativity had substantially longer progression-free and all round survivals, irrespectively with the treatment received.18 Sadly, even so, a few of these research have been flawed by inappropriate statistical analysis, especially the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are lots of caveats for the use of MRD analysis in patients with CLL.28 Initial, CLL remains incurable and a minimum of 30 of patients who attain MRD negativity after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC sooner or later experience a illness relapse inside five years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity soon after an initial MRD-negative response when compared with remedy at the time of clinical relapse. In fact, very couple of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some on the strategies tested, even though effective, resulted in important toxicity.33-35 Thirdly, it might be argued that MRD assessment is basically a surrogate for evalution of other adverse prognostic markers due to the fact, for example, sufferers with a 17p014 Ferrata Storti Foundation. That is an open-access paper. doi:10.3324/haematol.2013.099796 The on the web version of this article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(5)R. Santacruz et al.deletion possess a greater probability of remaining MRD-positive just after therapy in comparison to sufferers with no this chromosome abnormality.18 For all these causes, existing guidelines for the management of individuals with CLL propose MRD assessment only inside clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the impact of MRD around the outcome of sufferers with CLL receiving any front-line therapy inside the context of an incredibly detailed prognostic evaluation, like not too long ago described recurrent gene mutations.survival and general survival had been calculated employing a landmark evaluation. All calculations had been performed using either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 had been thought of statistically significant. A detailed explanation from the statistical strategies is offered within the On the internet Supplement.Benefits Baseline characteristicsThe median age from the entire cohort was 58 years (variety, 27-93 years), as well as the percentage of individuals older than 70 years was 22 . | |
Версія за 04:28, 23 січня 2018
These sufferers are viewed as to have achieved a minimal residual illness (MRD) negative status.17-20 Various phase II trials have demonstrated that sufferers reaching MRD negativity have a signif-icantly longer survival than people that stay MRD optimistic, and that is true for patients treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 In addition, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers getting MRD negativity had drastically longer progression-free and overall survivals, irrespectively in the therapy received.18 Unfortunately, nonetheless, some of these research have been flawed by inappropriate statistical evaluation, specifically the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are many caveats to the use of MRD evaluation in sufferers with CLL.28 First, CLL remains incurable and at the least 30 of sufferers who achieve MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point practical experience a disease relapse within five years.18 Secondly, unlike the scenario in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic benefit of re-treatment upon STF 62247 site documentation of MRD positivity immediately after an initial MRD-negative response in comparison to therapy at the time of clinical relapse. These sufferers are viewed as to have achieved a minimal residual disease (MRD) damaging status.17-20 Quite a few phase II trials have demonstrated that individuals attaining MRD negativity possess a signif-icantly longer survival than individuals who remain MRD positive, and that is correct for patients treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 In addition, a phase III trial performed by the German CLL Study Group (GCLLSG) recently revealed that individuals acquiring MRD negativity had substantially longer progression-free and all round survivals, irrespectively with the treatment received.18 Sadly, even so, a few of these research have been flawed by inappropriate statistical analysis, especially the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are lots of caveats for the use of MRD analysis in patients with CLL.28 Initial, CLL remains incurable and a minimum of 30 of patients who attain MRD negativity after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC sooner or later experience a illness relapse inside five years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity soon after an initial MRD-negative response when compared with remedy at the time of clinical relapse. In fact, very couple of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some on the strategies tested, even though effective, resulted in important toxicity.33-35 Thirdly, it might be argued that MRD assessment is basically a surrogate for evalution of other adverse prognostic markers due to the fact, for example, sufferers with a 17p014 Ferrata Storti Foundation. That is an open-access paper. doi:10.3324/haematol.2013.099796 The on the web version of this article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(5)R. Santacruz et al.deletion possess a greater probability of remaining MRD-positive just after therapy in comparison to sufferers with no this chromosome abnormality.18 For all these causes, existing guidelines for the management of individuals with CLL propose MRD assessment only inside clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the impact of MRD around the outcome of sufferers with CLL receiving any front-line therapy inside the context of an incredibly detailed prognostic evaluation, like not too long ago described recurrent gene mutations.survival and general survival had been calculated employing a landmark evaluation. All calculations had been performed using either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 had been thought of statistically significant. A detailed explanation from the statistical strategies is offered within the On the internet Supplement.Benefits Baseline characteristicsThe median age from the entire cohort was 58 years (variety, 27-93 years), as well as the percentage of individuals older than 70 years was 22 .
